[
  {
    "question": {
      "question_id": "cs03_q01_longitudinal",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "longitudinal",
      "prompt": "Based on the trial data so far, are there any emerging safety signals in the lab panels?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the adverse signal is hepatic (ALT/AST elevation), not renal \u2014 kidney function markers remain stable while liver enzymes diverge",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q01_longitudinal",
      "answer_text": "No results were found based on the search for emerging safety signals in lab panels within the trial data. Therefore, there is insufficient information to identify any emerging safety signals from lab panels at this time [ref_id: not available].",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_413068d0f1374efcb948d346",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 752
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_413068d0f1374efcb948d346",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_2607b394cf2342deb19c6867",
              "name": "memory_search",
              "arguments": {
                "query": "emerging safety signals lab panels trial",
                "filters": {
                  "scope_id": "trial_data"
                }
              }
            }
          ],
          "tokens_used": 1058
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_2607b394cf2342deb19c6867",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "No results were found based on the search for emerging safety signals in lab panels within the trial data. Therefore, there is insufficient information to identify any emerging safety signals from lab panels at this time [ref_id: not available].",
          "tokens_used": 1117
        }
      ],
      "tool_calls_made": 2,
      "total_tokens": 2927,
      "wall_time_ms": 3536.785615957342,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q02_null",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "null_hypothesis",
      "prompt": "What was the enrollment count at Site 03 in the Week 6 summary?",
      "ground_truth": {
        "canonical_answer": "The enrollment figure as documented in the Week 6 site summary.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_006"
        ],
        "key_facts": []
      }
    },
    "answer": {
      "question_id": "cs03_q02_null",
      "answer_text": "I couldn't find any information regarding the enrollment count at Site 03 in the Week 6 summary. The search returned no results.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_273f9884b2d7478fb5c7f9d5",
              "name": "memory_search",
              "arguments": {
                "query": "Week 6 summary Site 03 enrollment count",
                "filters": {
                  "scope_id": "weekly_summaries"
                }
              }
            }
          ],
          "tokens_used": 776
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_273f9884b2d7478fb5c7f9d5",
              "content": "[]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "I couldn't find any information regarding the enrollment count at Site 03 in the Week 6 summary. The search returned no results.",
          "tokens_used": 818
        }
      ],
      "tool_calls_made": 1,
      "total_tokens": 1594,
      "wall_time_ms": 2548.8446219824255,
      "budget_violations": [],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  },
  {
    "question": {
      "question_id": "cs03_q13_paraphrase",
      "scope_id": "clinical_signal_03",
      "checkpoint_after": 12,
      "question_type": "paraphrase",
      "prompt": "Are any laboratory parameters trending outside normal limits in specific patient populations?",
      "ground_truth": {
        "canonical_answer": "ALT values are creeping upward in a subset of patients, specifically those on concomitant statin therapy. The elevations are still below protocol action thresholds but the trend across multiple weeks is notable.",
        "required_evidence_refs": [
          "clinical_signal_03_ep_010",
          "clinical_signal_03_ep_013"
        ],
        "key_facts": [
          "ALT elevations are concentrated in subjects receiving concurrent statin therapy, with higher-dose statin subgroups showing proportionally greater enzyme increases",
          "multi-site signal distribution rules out site-specific confounders as causal explanation",
          "ALT elevations appeared progressively over multiple weeks of statin co-administration with onset timing correlating with cumulative exposure duration rather than a single acute event",
          "the ALT elevation pattern correlates with statin co-administration timing, not with immune activation or antibody response patterns",
          "musculoskeletal safety endpoints track within expected ranges, confirming the safety signal is organ-specific to the liver"
        ]
      }
    },
    "answer": {
      "question_id": "cs03_q13_paraphrase",
      "answer_text": "Yes, laboratory parameters in the statin concomitant subgroup show trends suggestive of potential abnormalities, particularly in liver enzymes and renal markers.\n\nIn the statin subgroup, ALT (alanine aminotransferase) levels increased from a mean of 37.2 U/L on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 47.6 U/L on 2024-05-13 [ref_id: clinical_signal_03_ep_011], indicating a rising trend in liver enzyme elevation. Similarly, creatinine levels in this subgroup showed variability, decreasing from a mean of 1.09 mg/dL on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 0.8 mg/dL on 2024-05-13 [ref_id: clinical_signal_03_ep_011], which may reflect fluctuating renal function or physiological variation.\n\nThese changes were observed in a subgroup of patients using statins concomitantly, with enrollment numbers increasing over time (e.g., 54 patients on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 55 on 2024-05-13 [ref_id: clinical_signal_03_ep_011]). While median values and other parameters such as bilirubin and AST remained relatively stable, the upward trend in ALT warrants monitoring for potential hepatotoxicity in this population.",
      "turns": [
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_b0b12de4bc234064b608c8c8",
              "name": "memory_capabilities",
              "arguments": {}
            }
          ],
          "tokens_used": 746
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_b0b12de4bc234064b608c8c8",
              "content": "{\"search_modes\": [\"keyword\", \"semantic\"], \"filter_fields\": [{\"name\": \"scope_id\", \"field_type\": \"string\", \"description\": \"Filter by scope ID\", \"enum_values\": null}, {\"name\": \"start_date\", \"field_type\": \"string\", \"description\": \"Filter episodes after this ISO date\", \"enum_values\": null}, {\"name\": \"end_date\", \"field_type\": \"string\", \"description\": \"Filter episodes before this ISO date\", \"enum_values\": null}], \"max_results_per_search\": 7, \"supports_date_range\": true, \"extra_tools\": [{\"name\": \"batch_retrieve\", \"description\": \"Retrieve multiple full documents by their reference IDs in a single call. PREFER this over calling memory_retrieve multiple times \\u2014 it is far more efficient and uses only one tool call instead of one per document. After memory_search, pass all ref_ids you want to read to this tool.\", \"parameters\": {\"type\": \"object\", \"properties\": {\"ref_ids\": {\"type\": \"array\", \"items\": {\"type\": \"string\"}, \"description\": \"List of reference IDs to retrieve (from search results).\"}}, \"required\": [\"ref_ids\"]}}]}",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_a5784605e4e340d4a49ce576",
              "name": "memory_search",
              "arguments": {
                "query": "laboratory parameters trending outside normal limits in patient populations",
                "limit": 7
              }
            }
          ],
          "tokens_used": 1050
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_a5784605e4e340d4a49ce576",
              "content": "[{\"ref_id\": \"clinical_signal_03_ep_008\", \"text\": \"## 2024-04-22 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 180\\n- Active: 177\\n- Screen Failures Cumulative: 13\\n- Withdrawals Cumulative: 3\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 13\\n- Site 02 Active: 13\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 16\\n- Site 03 Active: 16\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.03278688524590164, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_007\", \"text\": \"## 2024-04-15 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 160\\n- Active: 156\\n- Screen Failures Cumulative: 15\\n- Withdrawals Cumulative: 4\\n\\n#### Sites\\n- Site 01 Enrolled: 16\\n- Site 01 Active: 16\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 12\\n- Site 02 Active: 12\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 15\\n- Site 03 Active: 15\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 10\\n- Site 04 Active: 10\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 13\\n- Site \", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_011\", \"text\": \"## 2024-05-13 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 55\\n- ALT (U/L) Mean: 47.6\\n- ALT (U/L) Median: 47.4\\n- AST (U/L) Mean: 35.8\\n- AST (U/L) Median: 34.3\\n- Bilirubin (mg/dL) Mean: 0.7\\n- Bilirubin (mg/dL) Median: 0.67\\n- ALP (U/L) Mean: 67.5\\n- ALP (U/L) Median: 61.8\\n- Creatinine (mg/dL) Mean: 0.8\\n- Creatinine (mg/dL) Median: 0.86\\n- BUN (mg/dL) Mean: 13.5\\n- BUN (mg/dL) Median: 15.1\\n- WBC (K) Mean: 6.7\\n- WBC (K) Median: 5.6\\n- Platelets (K) Mean: 258\\n- Platelets (K) Median: 2\", \"score\": 0.031054405392392875, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_009\", \"text\": \"## 2024-04-29 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 185\\n- Active: 180\\n- Screen Failures Cumulative: 22\\n- Withdrawals Cumulative: 5\\n\\n#### Sites\\n- Site 01 Enrolled: 18\\n- Site 01 Active: 18\\n- Site 01 Statin Concomitant: 5\\n- Site 02 Enrolled: 14\\n- Site 02 Active: 14\\n- Site 02 Statin Concomitant: 4\\n- Site 03 Enrolled: 17\\n- Site 03 Active: 17\\n- Site 03 Statin Concomitant: 4\\n- Site 04 Enrolled: 12\\n- Site 04 Active: 12\\n- Site 04 Statin Concomitant: 3\\n- Site 05 Enrolled: 15\\n- Site \", \"score\": 0.031024531024531024, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_004\", \"text\": \"## 2024-03-25 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 100\\n- Active: 98\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01\\n  - Enrolled: 10\\n  - Active: 10\\n  - Statin Concomitant: 2\\n- Site 02\\n  - Enrolled: 7\\n  - Active: 7\\n  - Statin Concomitant: 1\\n- Site 03\\n  - Enrolled: 9\\n  - Active: 9\\n  - Statin Concomitant: 2\\n- Site 04\\n  - Enrolled: 6\\n  - Active: 6\\n  - Statin Concomitant: 1\\n- Site 05\\n  - Enrolled: 8\\n  - Active: 8\\n  - Statin Concomitant: 2\\n- S\", \"score\": 0.03076923076923077, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}, {\"ref_id\": \"clinical_signal_03_ep_010\", \"text\": \"## 2024-05-06 Daily Operations Summary\\n### Lab Panels\\n#### Statin Subgroup\\n- N: 54\\n- ALT (U/L) Mean: 37.2\\n- ALT (U/L) Median: 35.2\\n- AST (U/L) Mean: 32.1\\n- AST (U/L) Median: 30.9\\n- Bilirubin (mg/dL) Mean: 0.68\\n- Bilirubin (mg/dL) Median: 0.65\\n- ALP (U/L) Mean: 65.1\\n- ALP (U/L) Median: 62.3\\n- Creatinine (mg/dL) Mean: 1.09\\n- Creatinine (mg/dL) Median: 0.88\\n- BUN (mg/dL) Mean: 17.8\\n- BUN (mg/dL) Median: 16.4\\n- WBC (K/\\u00b5L) Mean: 6.3\\n- WBC (K/\\u00b5L) Median: 6.7\\n- Platelets (K/\\u00b5L) Mean: 245\\n- Platelets (K\", \"score\": 0.03055037313432836, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"early_signal\", \"signal_density\": \"low\"}}, {\"ref_id\": \"clinical_signal_03_ep_005\", \"text\": \"## 2024-04-01 Daily Operations Summary\\n\\n### Enrollment\\n- Total Randomized: 120\\n- Active: 118\\n- Screen Failures Cumulative: 11\\n- Withdrawals Cumulative: 2\\n\\n#### Sites\\n- Site 01 Enrolled: 12\\n- Site 01 Active: 12\\n- Site 01 Statin Concomitant: 4\\n- Site 02 Enrolled: 9\\n- Site 02 Active: 9\\n- Site 02 Statin Concomitant: 3\\n- Site 03 Enrolled: 11\\n- Site 03 Active: 11\\n- Site 03 Statin Concomitant: 3\\n- Site 04 Enrolled: 8\\n- Site 04 Active: 8\\n- Site 04 Statin Concomitant: 2\\n- Site 05 Enrolled: 10\\n- Site 05 A\", \"score\": 0.03036576949620428, \"metadata\": {\"episode_type\": \"signal\", \"phase\": \"baseline\", \"signal_density\": \"none\"}}]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "",
          "tool_calls": [
            {
              "id": "call_590788d65e0544aeb1d92468",
              "name": "batch_retrieve",
              "arguments": {
                "ref_ids": [
                  "clinical_signal_03_ep_011",
                  "clinical_signal_03_ep_010",
                  "clinical_signal_03_ep_008",
                  "clinical_signal_03_ep_007",
                  "clinical_signal_03_ep_009",
                  "clinical_signal_03_ep_004",
                  "clinical_signal_03_ep_005"
                ]
              }
            }
          ],
          "tokens_used": 3327
        },
        {
          "role": "tool",
          "tool_results": [
            {
              "tool_call_id": "call_590788d65e0544aeb1d92468",
              "content": "[Context budget exhausted \u2014 synthesize answer from evidence already retrieved]",
              "is_error": false
            }
          ],
          "tokens_used": 0
        },
        {
          "role": "assistant",
          "content": "Yes, laboratory parameters in the statin concomitant subgroup show trends suggestive of potential abnormalities, particularly in liver enzymes and renal markers.\n\nIn the statin subgroup, ALT (alanine aminotransferase) levels increased from a mean of 37.2 U/L on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 47.6 U/L on 2024-05-13 [ref_id: clinical_signal_03_ep_011], indicating a rising trend in liver enzyme elevation. Similarly, creatinine levels in this subgroup showed variability, decreasing from a mean of 1.09 mg/dL on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 0.8 mg/dL on 2024-05-13 [ref_id: clinical_signal_03_ep_011], which may reflect fluctuating renal function or physiological variation.\n\nThese changes were observed in a subgroup of patients using statins concomitantly, with enrollment numbers increasing over time (e.g., 54 patients on 2024-05-06 [ref_id: clinical_signal_03_ep_010] to 55 on 2024-05-13 [ref_id: clinical_signal_03_ep_011]). While median values and other parameters such as bilirubin and AST remained relatively stable, the upward trend in ALT warrants monitoring for potential hepatotoxicity in this population.",
          "tokens_used": 3701
        }
      ],
      "tool_calls_made": 3,
      "total_tokens": 8824,
      "wall_time_ms": 14742.561031947844,
      "budget_violations": [
        "Cumulative result token limit exceeded: 7575 > 4096"
      ],
      "refs_cited": []
    },
    "retrieved_ref_ids": [],
    "valid_ref_ids": []
  }
]